Wisdom Pharmaceuticals (300149): Revenue Growth Rate Improves Waiting for Transformation Results
Wisdom Pharmaceuticals (300149): Performance meets expectations, waiting for transformation results
Wisdom Pharmaceuticals (300149): Established CRO sets sail again and ushered in an inflection point in development
Wise Pharmaceutical (300149): performance growth trend upward Biopharmaceuticals CDMO business new production capacity is about to be put into production
Wise Pharmaceutical (300149): the performance growth is in line with market expectations and the growth trend of CXO business is clear and upward.
Quantum Biology (300149): significant improvement in second quarter results CRO long-term value return
Quantum Biology (300149): Core CRO business is at a turning point, biopharmaceutical CDMO business is about to launch
Quantum Biology (300149): the improvement of CRO service is optimistic that the volume CDMO service is ready to go.
Quantum Biology (300149): plans to issue H shares dual capital platform to speed up capacity upgrading
Quantum Biology (300149): Preclinical CRO leadership, CDMO integrated release is imminent
量子生物(300149):外资投资评级报告(海外机构投资评级C)
量子生物(300149):业绩符合预期 CRO板块维持高速增长
量子生物(300149):微生态健康与CRO双轮驱动 未来业绩有望高速增长
量子生物(300149)深度报告:生物CRO+CMO领衔发展 微生态静待风口
量子生物(300149):业务转型与利润拐点突现
量子高科(300149):-迎市场发展良机业绩有望持续提升
【华安证券】量子高科2016年三季报:营收下滑系表象,实际营收增势良好
量子高科(300149)2016年三季报点评:营收下滑系表象 实际营收增势良好
量子高科(300149):益生元行业弄潮儿 翘首健康产业大蓝海
【中国银河】量子高科:战略合作稳步推进,公司业绩积极向好
No Data